Evidence Level
Vitex (Chasteberry), derived from *Vitex agnus-castus*, is supported by robust clinical evidence for its role in women's health, particularly in managing premenstrual syndrome (PMS). A pivotal randomized controlled trial (RCT) by Schellenberg (2001) demonstrated significant symptom reduction in 170 women using the Ze 440 extract, with a 52% improvement rate compared to 24% for placebo. This study highlighted the efficacy of vitex in alleviating PMS symptoms.
A systematic review and meta-analysis by Verkaik et al. (2017) further corroborated these findings, analyzing 14 RCTs and concluding a large pooled effect of vitex on reducing PMS symptoms compared to placebo. The review emphasized its effectiveness, particularly for psychological complaints, while noting limitations such as high risk of bias and heterogeneity.
The pharmacological mechanism of vitex is well-documented: diterpenes in the extract act as dopamine D2 receptor agonists in the anterior pituitary, reducing prolactin secretion. This regulation supports normal corpus luteum function and progesterone production, addressing symptoms associated with hyperprolactinemia (Wuttke et al., 2003). A double-blind placebo-controlled study by Wuttke et al. (2003) involving 60 women confirmed that chaste tree extract reduces serum prolactin levels and improves premenstrual mastodynia.
Overall, Vitex agnus-castus demonstrates a favorable safety profile and consistent efficacy in managing PMS symptoms, supported by multiple studies across different methodologies.